SEC Form 4 · accession 0001209191-18-055308
Intra-Cellular Therapies, Inc. · ITCI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Neumann
Officer — EVP, Chief Commercial Officer
Period of report
Oct 15, 2018
Accepted (ET)
Oct 17, 2018 · 4:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567514
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $18.59 | Oct 15, 2018 | A | 55,300 | A | — | Oct 14, 2028 | Common Stock | 55,300 | 55,300 | D |
| Restricted Stock UnitsF2,F3 | — | Oct 15, 2018 | A | 40,344 | A | — | — | Common Stock | 40,344 | 40,344 | D |
Explanation of responses
- F1The option vests as to one third of the shares on October 15, 2019, one third of the shares on October 15, 2020 and one third of the shares on October 15, 2021.
- F2Each restricted stock unit represents a contingent right to receive one share of common stock.
- F3The restricted stock units vest as to one third of the shares on October 15, 2019, one third of the shares on October 15, 2020 and one third of the shares on October 15, 2021.